Table 3.
Prevalence of expression of co-signaling molecules on tumor and tumor-infiltrating immune cells by immune status
| Patients | Tumor PD-L1 | Tumor B7-H3 | PD-1 CD8 TILs | PD-1 CD4 TILs | PD-L1 TIIs |
|---|---|---|---|---|---|
| All patients (n = 66) | 26% (17%, 37%) | 85% (74%, 92%) | 80% (69%, 88%) | 73% (61%, 82%) | 55% (43%, 66%) |
| Immunocompetent (n = 42) | 26% (15%, 41%) | 88% (75%, 95%) | 81% (67%, 90%) | 67% (52%, 79%) | 60% (44%, 73%) |
| Immunosuppressed (n = 24) | 21% (9%, 40%) | 75% (55%, 88%) | 88% (69%, 96%) | 83% (64%, 93%) | 46% (28%, 65%) |
| HIV (n = 8) | 0% (0%, 37%) | 50% (22%, 78%) | 100% (64%, 100%) | 88% (53%, 98%) | 50% (22%, 78%) |
| Other immunosuppresseda (n = 16) | 31% (14%, 56%) | 88% (64%, 97%) | 81% (57%, 93%) | 81% (57%, 93%) | 44% (23%, 67%) |
Positive expression defined as ≥ 5% expression by tumor cells, tumor-infiltrating CD8 T cells, or tumor-infiltrating immune cells (TII). 95% confidence intervals are in parentheses
aOther immunosuppressed includes 12 organ transplants and 4 of other etiology (CLL, inflammatory bowel disease on immunosuppression)